TW202304992A - 用於免疫效應細胞重導向的材料及方法 - Google Patents

用於免疫效應細胞重導向的材料及方法 Download PDF

Info

Publication number
TW202304992A
TW202304992A TW111112186A TW111112186A TW202304992A TW 202304992 A TW202304992 A TW 202304992A TW 111112186 A TW111112186 A TW 111112186A TW 111112186 A TW111112186 A TW 111112186A TW 202304992 A TW202304992 A TW 202304992A
Authority
TW
Taiwan
Prior art keywords
amino acid
seq
acid sequence
cdr2
cdr3
Prior art date
Application number
TW111112186A
Other languages
English (en)
Chinese (zh)
Inventor
渫凡 林
依安 懷特
亞當 茲沃拉克
拉庫馬 加內桑
傑森 侯
Original Assignee
美商健生生物科技公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商健生生物科技公司 filed Critical 美商健生生物科技公司
Publication of TW202304992A publication Critical patent/TW202304992A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW111112186A 2021-03-31 2022-03-30 用於免疫效應細胞重導向的材料及方法 TW202304992A (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US202163168605P 2021-03-31 2021-03-31
US202163168611P 2021-03-31 2021-03-31
US202163168621P 2021-03-31 2021-03-31
US202163168618P 2021-03-31 2021-03-31
US202163168628P 2021-03-31 2021-03-31
US63/168,618 2021-03-31
US63/168,621 2021-03-31
US63/168,611 2021-03-31
US63/168,605 2021-03-31
US63/168,628 2021-03-31

Publications (1)

Publication Number Publication Date
TW202304992A true TW202304992A (zh) 2023-02-01

Family

ID=83459998

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111112186A TW202304992A (zh) 2021-03-31 2022-03-30 用於免疫效應細胞重導向的材料及方法

Country Status (11)

Country Link
US (1) US20240182582A1 (https=)
EP (1) EP4314080A4 (https=)
JP (1) JP2024512135A (https=)
KR (1) KR20230163485A (https=)
AU (1) AU2022246607A1 (https=)
BR (1) BR112023020249A2 (https=)
CA (1) CA3214963A1 (https=)
IL (1) IL307312A (https=)
MX (1) MX2023011645A (https=)
TW (1) TW202304992A (https=)
WO (1) WO2022212470A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250017240A (ko) * 2022-05-27 2025-02-04 사노피 FC-조작을 갖는 NKp46 및 BCMA 변이체에 결합하는 자연 살해(NK) 세포 관여자
WO2024208818A1 (en) 2023-04-04 2024-10-10 Innate Pharma Modular chimeric antigen receptor
US12286475B2 (en) 2023-07-31 2025-04-29 Sanofi Anti-GPRC5D antibodies and compositions
WO2025122929A1 (en) * 2023-12-08 2025-06-12 Janssen Biotech, Inc. Gprc5d antibodies with enhanced effector function and uses thereof
WO2025137555A1 (en) * 2023-12-20 2025-06-26 Omniab, Inc. Polypeptides that bind to nkp46

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291714B1 (en) * 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
WO2007048186A1 (en) * 2005-10-25 2007-05-03 Baker Medical Research Institute Leukocyte-binding polypeptides and uses thereof
AU2008337517B2 (en) * 2007-12-14 2014-06-26 Novo Nordisk A/S Antibodies against human NKG2D and uses thereof
WO2010017103A2 (en) * 2008-08-04 2010-02-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Fully human anti-human nkg2d monoclonal antibodies
WO2011085178A1 (en) * 2010-01-11 2011-07-14 Trustees Of Dartmouth College Monomeric bi-specific fusion protein
CA2875543A1 (en) * 2012-06-21 2013-12-27 Sorrento Therapeutics, Inc. Antigen binding proteins that bind igf1r
US11227669B2 (en) * 2014-06-21 2022-01-18 Norbert Ikechukwu Nwankwo Computer aided drug resistance calculator calculating drug resistance using amprenavir as a case study
JP6822849B2 (ja) * 2014-06-27 2021-01-27 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 多重特異的ＮＫｐ４６結合タンパク質
AU2017237543B2 (en) * 2016-03-23 2020-02-06 Institut Pasteur Korea Antibody that binds to envelope glycoprotein of severe fever with thrombocytopenia syndrome virus, and use for same
AU2018219887B2 (en) * 2017-02-08 2024-08-15 Dragonfly Therapeutics, LLC Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
CN110461361A (zh) * 2017-02-10 2019-11-15 蜻蜓治疗公司 结合bcma、nkg2d和cd16的蛋白
JP7350756B2 (ja) * 2018-02-14 2023-09-26 アバ セラピューティクス アーゲー 抗ヒトｐｄ－ｌ２抗体
EP3765516A2 (en) * 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
CA3099308A1 (en) * 2018-05-21 2019-11-28 Compass Therapeutics Llc Compositions and methods for enhancing the killing of target cells by nk cells
EA202091977A1 (ru) * 2018-05-28 2021-02-09 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
HRP20240821T1 (hr) * 2018-08-27 2024-09-27 Affimed Gmbh Stanice nk čuvane zamrzavanjem, koje su prethodno ubačene uz protutijelni konstrukt
BR112022001368A2 (pt) * 2019-07-26 2022-05-24 Janssen Biotech Inc Proteínas que compreendem domínios de ligação ao antígeno de peptidase 2 relacionada à calicreína e seus usos
CA3248329A1 (en) * 2019-07-31 2025-11-29 F. Hoffmann-La Roche Ag Antibodies binding to gprc5d
CN110903402B (zh) * 2019-11-27 2023-02-28 中国药科大学 一种双特异性融合蛋白及其构建方法与应用

Also Published As

Publication number Publication date
MX2023011645A (es) 2023-12-14
KR20230163485A (ko) 2023-11-30
EP4314080A4 (en) 2025-06-04
BR112023020249A2 (pt) 2023-12-19
US20240182582A1 (en) 2024-06-06
IL307312A (en) 2023-11-01
JP2024512135A (ja) 2024-03-18
WO2022212470A3 (en) 2022-11-17
AU2022246607A1 (en) 2023-11-16
CA3214963A1 (en) 2022-10-06
WO2022212470A2 (en) 2022-10-06
EP4314080A2 (en) 2024-02-07
WO2022212470A9 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
KR102692379B1 (ko) Pd-1과 특이적으로 결합하는 항체 및 사용 방법
CN111434692B (zh) 抗cld18a2纳米抗体及其应用
KR102025848B1 (ko) 항―ｎｇｆ 조성물 및 그의 용도
CN107207604B (zh) 抗alk2抗体
CN108055848B (zh) 抗pacap抗体及其用途
KR20220167273A (ko) 항-코로나바이러스 항체 및 사용 방법
TW202304992A (zh) 用於免疫效應細胞重導向的材料及方法
AU2017250807A1 (en) Anti-PACAP antibodies and uses thereof
KR20220040483A (ko) 칼리크레인 관련 펩티다제 2 항원 결합 도메인을 포함하는 단백질 및 이의 용도
KR20160099087A (ko) 이중특이성 her2 항체 및 사용 방법
KR20170085552A (ko) Tnf 계열 리간드 삼량체를 포함하는 항원 결합 분자
KR102718129B1 (ko) cys80 접합된 면역글로불린
KR20150122761A (ko) Ｔ 세포 활성화 항원 결합 분자
KR20230041819A (ko) Hla-g 항원-결합 도메인을 포함하는 단백질 및 이의 용도
KR20150139909A (ko) Fap 및 dr5에 특이적인 이중특이성 항체, dr5에 특이적인 항체 및 사용 방법
KR20230017841A (ko) Cd3 항원 결합 도메인을 포함하는 단백질 및 이의 용도
US20250326852A1 (en) Materials and methods for targeting regulatory t cells for enhancing immune surveillance
CN114174536B (zh) 抗trem-1抗体及其用途
KR20230005234A (ko) 생합성 당단백질 집단
HK40040431B (zh) 双特异性her2抗体及使用方法